{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000061","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.178020+00:00","generated_at":"2026-05-31T20:21:44.265710+00:00","sec_items":["2.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ligand completes acquisition of APEIRON Biologics for $100M cash plus up to $28M contingent","bullets":["Ligand acquired all outstanding shares of APEIRON for $100M in cash at closing on July 15, 2024.","Additional contingent consideration up to $28M if QARZIBA royalties exceed predetermined thresholds by 2030 or 2034.","QARZIBA (dinutuximab beta) is approved for high-risk neuroblastoma; Ligand obtains royalty rights.","Acquisition funded from Ligand's available cash on hand; closing subject to 30-day shareholder objection period.","Deal structured as a definitive agreement first announced on July 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000061","json":"https://secwatch.observer/filing/0000886163-24-000061.json","markdown":"https://secwatch.observer/filing/0000886163-24-000061.md","text":"https://secwatch.observer/filing/0000886163-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000061/0000886163-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000061/lgnd-20240715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:21:44.265710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}